Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Pharmacol Res 155:104689
A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients (Report)
The lawsuit accuses Novo Nordisk of failing to warn patients and healthcare providers about the risk of NAION, a serious optic nerve condition
(Drug Des Devel Ther, 2020) specifically compared bioavailability between oral and subcutaneous BPC-157 in healthy volunteers
M., Boehncke, W
Reconstitution, sourcing, and COA questions welcome
US$ 24.20
US$ 24.93
US$ 20.40
US$ 23.91
US$ 21.62
US$ 27.05
US$ 21.41
US$ 23.69
